依达拉奉联合瑞舒伐他汀用于急性脑梗死治疗的治疗有效率及临床疗效分析

Therapeutic Efficiency and Clinical Efficacy of Edaravone Combined with Rosuvastatin for Acute Cerebral Infarction Treatment

目的分析依达拉奉联合瑞舒伐他汀用于急性脑梗死治疗的治疗有效率及临床疗效。方法选择2020年9月—2023年9月山东省寿光市人民医院神经内科收治的186例急性脑梗死患者为研究对象,通过电脑分组法分为单药组和联合组,每组93例。常规对症支持基础上,单药组使用舒伐他汀治疗,联合组加用依达拉奉治疗,比较两组疗效差异。结果联合组治疗有效率为96.77%,显著高于单药组的88.17%,差异有统计学意义(χ^(2)=4.944,P=0.026)。联合组炎症因子、颈动脉内膜中层厚度、斑块面积、神经功能评分、日常生活能力评分等指标均显著优于单药组,差异有统计学意义(P均<0.05)。患者治疗期间均未发生严重不良反应。结论依达拉奉与瑞舒伐他汀的联合治疗方案用于急性脑梗死治疗的效果确切,有效率高,安全性值得肯定。

Objective To analyze the therapeutic efficiency and clinical efficacy of edaravone combined with rosuvas⁃tatin for the treatment of acute cerebral infarction.Methods A total of 186 patients with acute cerebral infarction ad⁃mitted to the Department of Neurology of Shouguang People's Hospital in Shandong Province from September 2020 to September 2023 were selected as the study objects,and were divided into single drug group and combined group by computer grouping method,with 93 cases in each group.On the basis of routine symptomatic support,the mono⁃therapy group was treated with rosuvastatin and the combination group was treated with edaravone combined with rosu⁃vastatin.The difference of curative effect between the two groups was compared.Results The effective rate of the com⁃bination group was 96.77%,significantly higher than that of the monotherapy group(88.17%),and the difference was statistically significant(χ^(2)=4.944,P=0.026).Inflammatory factors,carotid intima-media thickness,plaque area,nerve function score and daily living ability score in combination group were significantly better than those in single drug group,and the difference was statistically significant(all P<0.05).No serious adverse reactions occurred during treat⁃ment.Conclusion The combination of Edaravone and rosuvastatin in the treatment of acute cerebral infarction is effec⁃tive,effective and safe.